<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01015729</url>
  </required_header>
  <id_info>
    <org_study_id>D961FC00008</org_study_id>
    <nct_id>NCT01015729</nct_id>
  </id_info>
  <brief_title>Study Comparing Esomeprazole and ASA Combined Together as One Capsule Versus These Medications Taken Separately</brief_title>
  <official_title>An Open-Label, Randomized, Single-Center, 3-Way Crossover Study Comparing The Therapeutic Efficacy of a Fixed Dose Combination Capsule of Esomeprazole 20 mg And Acetylsalicylic Acid (ASA) 81 mg With Free Combinations of ASA Tablet 81 mg And Esomeprazole 20 mg as a Capsule or Tablet in Patients At Risk of Gastrointestinal Events Using Low Dose ASA for Cardiovascular Protection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether a fixed dose combination (FDC) capsule of
      esomeprazole 20 mg and acetylsalicylic acid (ASA) 81 mg has equivalent therapeutic efficacy
      compared to each of 2 free combinations of ASA tablet 81 mg plus esomeprazole 20 mg in
      patients at risk of gastrointestinal events using low dose ASA for cardiovascular protection.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of time that intragastric pH is maintained &gt; 4.0 during the 24-hour recording period</measure>
    <time_frame>pH is measured over a 24-hour period following dosing on Day 5 after repeated oral administartion/dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of time that intragastric pH is maintained &gt; 3.0 during the 24-hour recording period</measure>
    <time_frame>pH is measured over a 24-hour period following dosing on Day 5 after repeated oral administartion/dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median 24-hour intragastric pH</measure>
    <time_frame>pH is measured over a 24-hour period following dosing on Day 5 after repeated oral administartion/dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal symptom (Global Overall Symptoms questionnaire)</measure>
    <time_frame>GOS questionnaire will be adminsited on day 5</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Peptic Ulcer Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Esomeprazole 20 mg/ASA 81 mg Fixed Dose Combination Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Esomeprazole Clinical Trial Capsule 20 mg and 1 Aspirin® Non Enteric Coated Immediate Release Tablet 325 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Esomeprazole MUPS Tablet 20 mg and 1 Aspirin® Non Enteric Coated Immediate Release Tablet 325 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole/ASA Fixed Combination</intervention_name>
    <description>Capsule, oral, single dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>oral, single dose</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>Nexium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASA</intervention_name>
    <description>Tablet, oral, single dose</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>Aspirin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-smoking male and female subjects, aged 18 years or older with a documented history
             of uncomplicated peptic ulcer(s), or aged 65 years or older

          -  Body Mass Index (BMI = weight/height2) greater than or equal to 18.5 kg/m2 and less
             than or equal to 35.0 kg/m2

        Exclusion Criteria:

          -  Known history of hypersensitivity to esomeprazole (e.g. Nexium®) or related drugs such
             as omeprazole (e.g. Losec®, Prilosec®), lansoprazole (e.g. Prevacid®, Hp-PAC®),
             pantoprazole (e.g. Pantoloc®, PANTO® IV), or rabeprazole (e.g. Pariet™), a known
             hypersensitivity to ASA (e.g. Aspirin®) and/or related drugs such as ibuprofen (e.g.
             Motrin®, Advil®), indomethacin (e.g. Indocin®), diclofenac (e.g. Voltaren®), naproxen
             (e.g. Aleve®, Naprosyn®), or ketoprofen (e.g. Rhovail®).

          -  Significant history of pulmonary, endocrine, musculoskeletal, neurological,
             hematological, liver or kidney disease, or gastrointestinal disease (with the
             exception of uncomplicated peptic ulcer), unless deemed NCS by the Principal
             Investigator or Sub-investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>TJorgen Nasdal, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre Geoffroy, M.D. C.M., M.Sc., F.C.F.P.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biovail Contract Research (BCR)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2009</study_first_submitted>
  <study_first_submitted_qc>November 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2009</study_first_posted>
  <last_update_submitted>January 13, 2012</last_update_submitted>
  <last_update_submitted_qc>January 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>ASA</keyword>
  <keyword>Esomeprazole</keyword>
  <keyword>peptic ulcer disease</keyword>
  <keyword>pH measurements</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peptic Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

